Marshall Wace LLP Makes New $1.45 Million Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

Marshall Wace LLP purchased a new position in UroGen Pharma Ltd. (NASDAQ:URGN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 136,491 shares of the company’s stock, valued at approximately $1,454,000.

Several other institutional investors also recently added to or reduced their stakes in URGN. Rhumbline Advisers raised its stake in shares of UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after purchasing an additional 1,402 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in UroGen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after buying an additional 3,024 shares during the period. Legal & General Group Plc increased its holdings in UroGen Pharma by 24.6% in the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company’s stock valued at $211,000 after buying an additional 3,920 shares during the period. KLP Kapitalforvaltning AS bought a new stake in UroGen Pharma in the 4th quarter valued at $59,000. Finally, Wells Fargo & Company MN increased its holdings in UroGen Pharma by 2.7% in the 4th quarter. Wells Fargo & Company MN now owns 221,540 shares of the company’s stock valued at $2,359,000 after buying an additional 5,801 shares during the period. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Stock Up 14.1 %

Shares of NASDAQ:URGN opened at $11.26 on Tuesday. The company’s fifty day moving average is $10.44 and its 200-day moving average is $11.08. The company has a market capitalization of $519.02 million, a PE ratio of -3.57 and a beta of 0.80. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma Ltd. has a 52 week low of $8.94 and a 52 week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to analyst estimates of $25.25 million. Equities research analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This represents a 21.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on URGN shares. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of UroGen Pharma in a report on Monday. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday. LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target on the stock. Scotiabank started coverage on shares of UroGen Pharma in a report on Wednesday, April 16th. They issued a “sector outperform” rating and a $23.00 price target on the stock. Finally, The Goldman Sachs Group reduced their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma presently has an average rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.